Kidney Disease
Finerenone slows kidney decline in non-diabetic CKD trial; pooled analysis suggests broader benefits across CKD
An Ruwaito ta hanyar AI Hoton da AI ya samar An Binciki Gaskiya
New data presented at the European Renal Association’s 63rd Congress in Glasgow and published in three major medical journals found that finerenone slowed kidney-function decline in adults with chronic kidney disease (CKD) without diabetes and reduced the risk of a combined kidney-and-cardiovascular outcome. A separate pooled analysis that combined results across finerenone studies also reported fewer kidney and heart-failure events in a broader CKD population.
A nationwide study has revealed that almost half of Americans referred for a kidney transplant never begin the required evaluation process. Only 19 percent ultimately reach the transplant waitlist. The research highlights major disparities tied to social, geographic, and medical factors.
An Ruwaito ta hanyar AI
A clinic at Groote Schuur Hospital in Cape Town is providing tailored care for adolescents and young adults with kidney disease, helping them transition from pediatric services. The Kidney Adolescent and Young Adult Clinic, known as Kayac, has shown improved survival rates and lower dropout compared to standard adult care.